ISSN: 2249–9504
CAS CODEN: IJPCDX

FORMULATION DEVELOPMENT AND IN-VITRO EVALUATION OF ESCITALOPRAM OXALATE ORALLY DISINTEGRATING TABLETS

Abstract

Author(s): Ramesh Kannuri, Hareesha Chamarthi, Senthil Kumar. M, Threveen challa and Agaiah Goud.

The purpose of this research was to develop Orally disintegrating tablets of escitalopram Oxalate. Orally disintegrating tablets offers a solution for paediatrics, geriatrics; psychiatric or mentally ill people and those have difficulty in swallowing tablets/capsules resulting in improved patient compliance. Selective serotonin reuptake inhibitors (SSRIs), which are broad spectrum antidepressants that are effective for major depressive disorder and several anxiety disorders. Escitalopram Oxalate is highly selective, more effective and better than other SSRIs. The aim is to formulate Orally disintegrating tablets of escitalopram oxalate using different ratios of Superdisintegrants LHPC-21, Kyron and Crospovidone, while Microcrystalline cellulose, Mannitol, Prosolv ODT used as fillers. Tablets were prepared by direct compression method. The tablets were evaluated for hardness, thickness, friability, and weight variation and disintegration time, dispersion times and %drug release studies were performed. Tablets containing Crospovidone, Kyron as disintegrants and Mannitol as filler were disintegrate rapidly below 20 sec and 100% drug release below 5mins.

Get the App